Immunis Appoints Neil Sahota as Chief Artificial Intelligence Officer
Immunis Appoints Mark Cabato as Chief Business Officer
GHP magazine has a readership of over 110,000, providing exposure for biotech companies like Immunis to share their biomedical mission with the masses. This year, Immunis’ investigational stem cell-derived secretome product (STEM) was the outstanding competitor.
STEM was created to address the age-related decline in immune system health, which manifests in conditions such as Alzheimer’s disease, cancer and sarcopenia. As we age, our immune system function declines and we experience a decrease in the production of beneficial cellular secretions. These secretions, collectively referred to as the secretome, are necessary for modulating immune responses to combat disease.
Conditions like sarcopenia are an important risk factor for disability and mortality. However, mitigating the loss of muscle and improving muscle recovery are unmet medical needs. Remarkably, preclinical researchshows that the STEM secretome enhances muscle size and strength following atrophy. Immunis is amid a Phase 1/2a clinical trial to investigate the safety and efficacy of STEM in patients with muscle atrophy associated with knee osteoarthritis.
“Due to its multi-component mix of molecules associated with cellular function and tissue remodeling, I wouldn’t be surprised if STEM has large, beneficial impacts on other manifestations of age-related diseases,” said Professor Drummond, Scientific Advisory Board Member of Immunis.
Immunis is honored by GHP’s recognition of STEM as this year’s “Best Immune Deficit Treatment Development” and is looking forward to assessing the results of our ongoing clinical trial. Immunis would also like to express gratitude to its incredibly talented and dedicated team that strives to enhance human health.
About Global Health and Pharma
GHP magazine serves as an informational platform for healthcare and pharmaceutical industries. With a circulation of 110,000 globally, GHP aims to support and showcase the latest and most promising innovations across the medical and health industries. For more information please visit: www.ghp-news.com
About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technologies to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: www.immunisbiomedical.com
About STEM-MYO
Immunis’ FDA-awarded Phase 1/2a clinical trial is an open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in elderly participants with muscle atrophy associated with knee osteoarthritis. Up to 18 patients will be enrolled in the trial and randomly assigned to an IMM01-STEM dose cohort. Treatment will be administered in the form of intramuscular injections twice a week for four weeks (8 injections total). Male or female patients are eligible for the study if they satisfy the following criteria: (1) 50 to 75 years of age at the time of signing the informed consent, (2) have a grade 2 or 3 knee osteoarthritis as defined by Kellgren-Lawrence analyses, (3) have quadricep weakness (<7.5N/kg), (4) can ambulate >50 feet unassisted, (5) are negative for human immunodeficiency virus, hepatitis B surface antigen (HBsAg), and hepatitis C at the Screening Visit and (6) have a body mass index (BMI) of <40kg/m2. For additional information about Immunis’ trial participant qualifications, please visit: www.immunisbiomedical.com
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
###